Conclusions
ovarian cancer, platinum-sensitive ovarian cancer, platinum-sensitive, -resistant recurrent
BREAST CANCER
Given the subsequent lack of efficacy demonstrated for iniparib in breast cancer, these are studies of GC and demonstrate a higher than traditionally appreciated activity in patients with platinum-sensitive and -resistant recurrent ovarian cancer, especially in patients that harbor a This article evaluates the potential efficacy of iniparib in combination with gemcitabine and carboplatin in platinum-sensitive ovarian cancer.